This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Actuate Therapeutics Inc ACTU
$1.11
▼ -5.13%
($-0.06)
🎈 Low Float
🗓️ Earnings Next Week
Open
$1.19
Prev Close
$1.17
Day Range
$1.09 – $1.21
52W Range
$1.03 – $9.22
Market Cap
$26.56M
Beta
1.89
EPS (TTM)
$-0.99
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-08-13 |
| Shares Out. | 23,930,000 |
| Website | actuatetherapeutics.com/ ↗ |
| Phone | 18479864190 |
| Employees | 12 |
| Net Income | -$5.6M |
| Total Assets | $8.9M |
| Total Liabilities | $5.1M |
| Equity | $3.8M |
About Actuate Therapeutics Inc
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Actuate Therapeutics Inc is a publicly traded company under the ticker symbol ACTU on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-07-01)